Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00616200
Other study ID # 05-2899
Secondary ID GCRC 2392
Status Completed
Phase N/A
First received February 5, 2008
Last updated September 13, 2017
Start date August 2009
Est. completion date May 2010

Study information

Verified date October 2011
Source University of North Carolina, Chapel Hill
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purposes of this study are to prospectively determine the effect of a very low carbohydrate diet on quality of life and gastrointestinal symptoms in patients with diarrhea-predominant irritable bowel syndrome (IBS-D); and to determine possible physiological correlates of symptom improvement, as related to post-prandial 5-hydroxytryptamine (5-HT) release, weight loss and fiber content.


Description:

Approximately 10-15% of individuals in the United States have symptoms consistent with irritable bowel syndrome (IBS) which is a costly disorder and negatively impacts patient quality of life. The pathogenesis of this heterogeneous disorder is still not well understood. Patients frequently identify worsening of symptoms after meals and often cite particular foods as triggers of their IBS symptoms. Unfortunately, there is insufficient randomized clinical trial data to allow for specific dietary recommendations. Previous research has suggested a role for carbohydrate ingestion in IBS. There is also evidence for the role of the post-prandial release of 5-hydroxytryptamine (5-HT) and its turnover (as represented by the ratio of its metabolite, 5-hydroxyindoleacetic acid (5-HIAA), to 5-HT in response to a carbohydrate-rich meal, especially in those with IBS-D. As the prevalence of overweight (body mass index [BMI] > 25 kg/m2) and obesity (BMI > 30 kg/m2) has risen in recent years, very low carbohydrate diets have become popular for those attempting to lose weight. Patients with IBS, especially IBS-D, anecdotally report improvement in their gastrointestinal symptoms after initiating a very low carbohydrate diet. However, no study has investigated the effect of a very low carbohydrate diet on symptoms and quality of life in patients with IBS-D.


Recruitment information / eligibility

Status Completed
Enrollment 17
Est. completion date May 2010
Est. primary completion date May 2010
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

1. Age 18-70 years old, male or female

2. Meet Rome II Criteria for IBS-D

3. Body mass index > 25 kg/m^2

4. Desire to use a very low carbohydrate diet for weight loss

5. Score of > 36 on the FBDSI

6. Ability to understand consent form

7. In stable health by screening history, physical examination performed by a study physician, laboratory tests (normal blood counts, kidney function tests, liver tests, TSH).

Exclusion Criteria:

1. Age < 18 years or age > 70 years

2. History of inflammatory bowel disease

3. History of any gastrointestinal surgery that preceded the onset of IBS symptoms

4. Pregnancy or breastfeeding

5. FBDSI symptom score of = 36

6. Inability to understand consent form

7. Diabetes requiring medications (must be controlled with diet and exercise alone).

8. Chronic narcotic use for any reason

9. Use of serotonin-selective reuptake inhibitors unless patient has been on a stable dose for at least 4 weeks.

10. Use of any over-the-counter or prescription weight loss medications.

11. Any chronic or unstable diseases (e.g., kidney disease, heart disease, or cancer) that may put the subject at increased risk from the intervention

12. Any of the following baseline abnormalities of laboratory tests or physical exam findings:

1. Serum creatinine > 1.5 mg/dL in men, > 1.3 mg/dL in women.

2. Liver disease (AST or ALT > 2 times the upper limit of normal or total bilirubin > 1.6mg/dL).

3. Blood pressure > 160/100 mm Hg.

4. Fasting triglycerides > 600 mg/dL.

5. Fasting serum low-density lipoprotein (LDL) cholesterol > 190 mg/dL.

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Very low carbohydrate diet
4 weeks on strictly controlled low carbohydrate diet

Locations

Country Name City State
United States UNC Center for Functional GI & Motility Disorders Chapel Hill North Carolina

Sponsors (1)

Lead Sponsor Collaborator
University of North Carolina, Chapel Hill

Country where clinical trial is conducted

United States, 

References & Publications (1)

Austin GL, Dalton CB, Hu Y, Morris CB, Hankins J, Weinland SR, Westman EC, Yancy WS Jr, Drossman DA. A very low-carbohydrate diet improves symptoms and quality of life in diarrhea-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol. 2009 Jun; — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Subjects Reporting "Adequate Relief" From IBS Symptoms for the Previous Week. Adequate Relief Was a "True/False" Item. Adequate relief was measured as the primary endpoint via a single item Adequate Relief Question asking "Over the past week have you had adequate relief of your symptom experience". Higher scores represent greater levels of adequate relief over the week prior to the assessment. Participants completed this 1-item questionnaire at the end of each of weeks of the study, assessing whether they had adequate relief of their IBS symptoms for the week.
A responder was defined as reporting adequate relief in at least 2 of the 4 weeks on the VLCD.
At the end of each of 6 study weeks
Secondary Impact of Very Low Carbohydrate Diet on Stool Frequency Stool Frequency was measured as number of stools per day 6 Weeks
Secondary Sickness Impact Profile Units of measurement on the Sickness Impact Profile were ordinal rated scored. Information on scoring use and interpretation of the Sickness Impact Profile, readers are encouraged to read Bergner et. al. 1981 - Bergner, M., Bobbit, R.A., Carter, W.B. et all (1981) the Sickness Impact Profile: Development and final revision of a health status measure. Medical Care, 19:787-805 The SIP measures sickness-related dysfunction based on behavior in order to provide a measure of health status that will aid in assessing the outcome of health care services. At the end of four week VLCD
See also
  Status Clinical Trial Phase
Terminated NCT02239926 - Effect of Ranolazine on Gastrointestinal Motor Function and Pain in Patients With IBS-D Phase 2/Phase 3
Completed NCT02251483 - Use of SBI in IBS Subjects Following a Successful Treatment of Small Intestinal Bacterial Overgrowth N/A
Completed NCT01896583 - A Phase 2 Pilot Study to Assess ASP7147 in Patients With Diarrhea Predominant Irritable Bowel Syndrome (IBS-D) Phase 2
Completed NCT01100684 - Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS) Phase 3
Completed NCT02728063 - Lactibiane Tolérance® in Individuals Suffering From Irritable Bowel Syndrome With Diarrheal Predominance N/A
Completed NCT02358694 - Safety and Tolerability of Serum Derived Bovine Immunoglobulin in Children With Diarrhea Predominant IBS N/A
Recruiting NCT01637714 - The Effects of Multi-strain Probiotics in Adults With Diarrhea Predominant Irritable Bowel Syndrome N/A
Not yet recruiting NCT01373034 - The Effects of Soy Dietary Fiber in Adults With Diarrhea Predominant Irritable Bowel Syndrome N/A
Completed NCT01094041 - Gluten Intolerance in Patients With Diarrhea Predominant Irritable Bowel Syndrome N/A
Completed NCT02111603 - Ability of Mayo Clinic High-performance Liquid Chromatography (HPLC) Method to Measure Fecal Bile Acids Phase 4